P3-081: Erlotinib as monotherapy for patients with advanced or metastatic non-small cell lung cancer (NSCLC) and poor performance (PS=2)  by Garcia, Ramon et al.
Copyright © 2007 by the International Association for the Study of Lung Cancer S713
Journal of Thoracic Oncology • Volume 2, Number 8, Supplement 4, August 2007  12th World Conference on Lung Cancer
Skin rash (62.2%), asthenia (34.1%) and diarrhoea (30.1%) were the 
most frequent toxicities. 
Conclusions: This subgroup analysis conﬁrms the activity of Erlotinib 
in male patients with advanced NSCLC. Survival beneﬁt was also evi-
dent and no differences between subgroups were observed (with the ex-
ception of performance status). This retrospective analysis, along with 
the subgroup analyses of the BR.21 study, suggests that at this moment, 
gender should not be a criterion to decide treatment with Erlotinib.
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Background: Poor performance status is one of the prognostic factors 
in patient with lung cancer; this group constitutes between 30%-40% 
of the patients with advanced non small cell lung cancer (NSCLC) and 
has a low life expectancy. Erlotinib, an oral inhibitor of the Epidermal 
Grow Factor (EGFR) have demonstrated to improve survival, prolong 
disease progression, and delay worsening of cancer-related symptoms, 
with a mild safety proﬁle, which make Erlotinib an ideal candidate to 
treat those patients with poor performance status (PS). Here we present 
results of an analysis of a large subgroup of patients with PS =2 in a 
Phase II prospective study (TargeT), in order to determine the efﬁcacy 
and safety of Erlotinib in that population.
Methods: Patient with histologically conﬁrmed stage IIIB or IV 
NSCLC, that were ≥ 18 year old, had adequate bone marrow, he-
patic, and renal function, were pretreated with chemotherapy or were 
untreated patients that were not suitable for ﬁrst line conventional 
chemotherapy were included in the TargeT trial. Patients with poor 
performance status (ECOG = 2) were included in this sub analysis. 
Patients were treated with Erlotinib single agent 150 mg/day p.o. until 
disease progression or withdrawal. Evaluation of the safety proﬁle was 
determined by NCI CTCAE version 3.0.
Results: 386 patients with poor PS and advanced NSCLC were ana-
lyzed in this study. Median age was 67 years (range 28-95), 99% of the 
patients were Caucasian, there was 73.8% males and 26.2% females. 
The stage of the patients was: IIIB/ 18.9% and IV 81.9%. The Histol-
ogy was adenocarcinoma / squamous / large cell / others 54%, 22%, 
18% and 6% respectively. First line patients were 35%, 2nd line 34% 
and 3rd line 31%. Current smokers or patients that have smoked were 
78%. In the population evaluable for response (148 patients), 1 CR, 23 
PR, 57 SD were observed (ORR 16.2%). Clinical beneﬁt (CR+PR+SD) 
was 54.7%. RR is much higher in females (34.8%) than males (8.6%) 
(p<0.0001) and in never smokers (45.7%) than in smokers (7.2%) 
(p<0.0001). Median TTP was 3.33 months (95% CI 2.7 - 5.1). The mul-
tivariate analysis showed that no smoking history correlated with better 
TTP (p<0.0025).Rash was the predominant toxicity occurring in 44.8% 
of the patients and diarrhea was observed in 24%, but only one grade 4 
was reported. 
Conclusions: Erlotinib is safe, well tolerated and active in patients 
with advanced NSCLC and poor performance status. In the multivariate 
analysis, smoking history is the main predictive factor. Further studies 
in this population are warranted.
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Background: Erlotinib is a selective EGFR inhibitor approved for the 
treatments of patients with non-small cell lung cancer (NSCLC) after 
failure of at least one prior chemotherapy. Although third line treatment 
is not often an option for NSCLC due to the decline in the performance 
status and to the aggravation of symptoms, here we present results of 
an analysis of a large subgroup of patients treated in third or more lines 
in a Phase II prospective study (TargeT).
Methods: Patients with IIIB-IV stage, performance status ≤2, adequate 
bone marrow, hepatic and renal functions, that were previously treated 
for advanced or metastastic NSCLC were included in the TargeT study. 
Erlotinib was given at a dose of 150 mg/day until disease progression 
or withdrawal. Results from patients who received at least two previous 
regimen of treatment were analyzed. Evaluation of response rate (ac-
cording to RECIST criteria), time to progression (TTP), survival and 
safety proﬁle was performed.
Results: 503 patients treated in the TargeT study were on third or 
further line of treatment. Median age was 60 years (range 32-84), 99 
% of them were Caucasian. All of them had received two or more 
previous therapies for metastatic disease. 82% of the patients were 
male and 88% were current or former smokers. Performance status 
0/1/2 was 20%/56%/24% respectively. In 43% of the patients tumor 
histology was adenocarcinoma. 293 patients had measurable disease 
and were evaluable for response. 2 CR, 30 PR (ORR 10.9%), 111 SD 
and 150 PD were observed. Rate of clinical beneﬁt (CR+PR+SD) was 
48.8%. RR was much higher in never smokers (36.4%) than in current 
or former smokers (7.4%, p<0.0001) and in women (25%) than in men 
(7.6%, p<0.0002). 
Analyzing the population by intention to treat median time to progres-
sion (TTP) was 3.2 months (95% CI 2.8–C3.7) and median survival 
time 5.6 months (95% CI 4.6–C6.4). The multivariate analysis showed 
that never smoking history was signiﬁcantly correlated with a better 
TTP (p<0.0026) and overall survival (OS) (p<0.0028).
Erlotinib was well tolerated and no unexpected toxicities were ob-
served. Rash and diarrhea were the most frequent adverse events.
